Twilight MasqueradeTwilight Masquerade🃏All Palafin cards
Ask about Palafin
Palafin #60 Pokémon card from Twilight Masquerade

Palafin 60/167

Twilight Masquerade

Find this card on eBay

Affiliate link · we may earn commission

Palafin #60 from Twilight Masquerade currently trades at $0.17 raw, with PSA 10 copies reaching $59.27 — a 348.6x grade premium.
Current Prices (USD)
Ungraded
$0.17
PSA 7
$10.49
PSA 8
$10.49
PSA 9
$10.49
PSA 10
$59.27
ACE 10
BGS 10 Black
$385.00
CGC 10 Pristine
$65.00
Compare on eBay

Affiliate link · we may earn commission

Quick price facts

Palafin 60/167 from Twilight Masquerade has a current raw market value of $0.17.

Current raw value
$0.17
PSA 9 value
$10.49
PSA 10 value
$59.27
View all cards from Twilight Masquerade
Collector Intel
348.6x
Raw → PSA 10
High-risk grade
61.7x
Raw → PSA 9
Grade multiplier

Calculated from price history, PSA population data, and market trends. Not financial advice.

Grading Calculator

Based on PSA Standard tier (~$25 USD). Assumes a perfect PSA 10 result — actual outcome depends on card condition.

⚠️ High-variance grade. PSA 10 is 349x the raw price. The expected value accounts for the realistic probability.
$0
Buy Raw
~$25
Grading Fee
PSA Standard
$59
PSA 10 Value
+$34
Best Case (PSA 10)
if you pull a 10
Grade Multiples vs Raw
PSA 9$1061.7x raw
PSA 10$59348.6x raw

Frequently asked questions

How much is Palafin #60 from Twilight Masquerade worth?+
Palafin #60 from Twilight Masquerade is currently worth Raw: $0.17, PSA 9: $10.49, PSA 10: $59.27 based on recent sold listings. Prices update daily from real eBay sales.
Is Palafin #60 worth grading?+
The PSA 10 price of $59.27 is 348.6× the raw price of $0.17. After a ~$25 grading fee, a PSA 10 result would net approximately $59.10 — assuming the card grades a 10.
Where do PokePrices Palafin #60 prices come from?+
Prices are tracked nightly from real sold listings on PriceCharting (raw, PSA 9 and PSA 10). PSA population data is sourced from PSA's public reports. We do not use asking prices — only confirmed sales.